BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more
BioArctic AB (publ) (BRCTF) - Total Assets
Latest total assets as of September 2025: $2.60 Billion USD
Based on the latest financial reports, BioArctic AB (publ) (BRCTF) holds total assets worth $2.60 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioArctic AB (publ) - Total Assets Trend (2015–2024)
This chart illustrates how BioArctic AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioArctic AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
BioArctic AB (publ)'s total assets of $2.60 Billion consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.1% |
| Accounts Receivable | $71.20 Million | 6.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how BioArctic AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioArctic AB (publ)'s current assets represent 90.9% of total assets in 2024, an increase from 90.3% in 2015.
- Cash Position: Cash and equivalents constituted 46.1% of total assets in 2024, down from 86.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 6.4% of total assets.
BioArctic AB (publ) Competitors by Total Assets
Key competitors of BioArctic AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BioArctic AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioArctic AB (publ) generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioArctic AB (publ) is currently not profitable relative to its asset base.
BioArctic AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.15 | 8.35 | 9.27 |
| Quick Ratio | 4.15 | 8.35 | 9.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.89 Billion | $ 871.21 Million | $ 899.64 Million |
BioArctic AB (publ) - Advanced Valuation Insights
This section examines the relationship between BioArctic AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.28 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | $1.11 Billion |
| Market Capitalization | $1.01 Billion USD |
Valuation Analysis
Near Book Valuation: The market values BioArctic AB (publ)'s assets close to their book value ( 0.91x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: BioArctic AB (publ)'s assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioArctic AB (publ) (2015–2024)
The table below shows the annual total assets of BioArctic AB (publ) from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.11 Billion | -6.27% |
| 2023-12-31 | $1.19 Billion | +38.19% |
| 2022-12-31 | $858.31 Million | -4.39% |
| 2021-12-31 | $897.73 Million | -14.53% |
| 2020-12-31 | $1.05 Billion | -11.24% |
| 2019-12-31 | $1.18 Billion | -15.05% |
| 2018-12-31 | $1.39 Billion | +22.14% |
| 2017-12-31 | $1.14 Billion | +61.09% |
| 2016-12-31 | $707.98 Million | +439.98% |
| 2015-12-31 | $131.11 Million | -- |